Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 7/20 | 0.37 |
| ▸ | MMP3 | P08254 | 7/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP14 | P50281 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796623 | 0.98 | PPARD (0.39) | PPARDMMP2MMP3MMP1MMP9 | |
| SCHEMBL19796620 | 0.91 | PPARG (0.35) | PPARDPPARGPPARADGAT1SOAT1 | |
| SCHEMBL19796630 | 0.91 | PPARD (0.38) | PPARDMMP2MMP3MMP1MMP9 | |
| SCHEMBL19796628 | 0.89 | PPARD (0.38) | PPARDPPARGPPARAGABRA1GABRB2 | |
| SCHEMBL19804730 | 0.88 | MMP2 (0.38) | PPARDMMP2MMP3MMP1MMP9 | |
| SCHEMBL19796618 | 0.88 | CYP2C9 (0.35) | PPARGPPARARARBPTPN11DGAT1 | |
| SCHEMBL19796538 | 0.87 | FFAR4 (0.33) | PPARDMMP2MMP3MMP1MMP9 | |
| SCHEMBL19796491 | 0.86 | MMP2 (0.33) | PPARDMMP2MMP3MMP1MMP9 | |
| SCHEMBL20171741 | 0.86 | PPARG (0.32) | PPARDPPARGPPARARARBTSHR | |
| SCHEMBL19007866 | 0.86 | PPARD (0.37) | PPARDMMP2MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | PPARD 3071/4885MMP2 3416/4885MMP3 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.